Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Stock analysts at Wedbush issued their Q1 2025 earnings estimates for Rezolute in a research report issued on Monday, November 4th. Wedbush analyst Y. Zhong forecasts that the company will post earnings per share of ($0.44) for the quarter. Wedbush has a "Outperform" rating and a $112.00 price objective on the stock. The consensus estimate for Rezolute's current full-year earnings is ($1.23) per share. Wedbush also issued estimates for Rezolute's Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.70) EPS, FY2026 earnings at ($1.52) EPS, FY2027 earnings at ($1.32) EPS, FY2028 earnings at ($0.61) EPS and FY2029 earnings at $0.16 EPS.
Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14).
A number of other research analysts have also issued reports on RZLT. BTIG Research lifted their target price on Rezolute from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, September 10th. Maxim Group lifted their price objective on Rezolute from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Tuesday, August 6th. HC Wainwright restated a "buy" rating and set a $14.00 target price on shares of Rezolute in a research note on Friday, September 27th. JMP Securities reiterated a "market outperform" rating and issued a $7.00 price target on shares of Rezolute in a research note on Friday, September 20th. Finally, Guggenheim started coverage on shares of Rezolute in a research report on Tuesday, August 27th. They issued a "buy" rating and a $11.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $24.13.
Get Our Latest Analysis on RZLT
Rezolute Price Performance
Rezolute stock traded down $0.09 during mid-day trading on Thursday, reaching $5.72. 234,875 shares of the company's stock were exchanged, compared to its average volume of 397,015. The company has a fifty day moving average of $5.01 and a 200-day moving average of $4.36. Rezolute has a twelve month low of $0.72 and a twelve month high of $6.10.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of RZLT. Federated Hermes Inc. grew its holdings in shares of Rezolute by 11.1% during the second quarter. Federated Hermes Inc. now owns 11,279,327 shares of the company's stock worth $48,501,000 after purchasing an additional 1,125,000 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in Rezolute by 15.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company's stock worth $7,955,000 after buying an additional 250,000 shares during the last quarter. Vanguard Group Inc. increased its position in Rezolute by 10.4% during the first quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company's stock worth $3,961,000 after buying an additional 145,700 shares during the period. Marshall Wace LLP purchased a new stake in Rezolute in the second quarter valued at approximately $4,503,000. Finally, Rosalind Advisors Inc. lifted its stake in Rezolute by 25.0% in the second quarter. Rosalind Advisors Inc. now owns 250,000 shares of the company's stock valued at $1,075,000 after buying an additional 50,000 shares during the last quarter. 82.97% of the stock is owned by hedge funds and other institutional investors.
About Rezolute
(
Get Free Report)
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
See Also
Before you consider Rezolute, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.
While Rezolute currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
